Leveraging its high accuracy and programmability, the CRISPR system emerges as a promising platform for advancing the identification of SNPs. In this study, we compared two type V CRISPR/Cas systems ...

New research has uncovered how the body clears dying cells during times of stress, shedding light on the unexpected role of ...

A newly discovered bacterial defense protein named Cat1 reveals an extraordinary method of viral neutralization. All living ...

Precision gene editing is crucial for treating genetic diseases, as it enables targeted correction of specific mutations. A ...

to target individual pieces of RNA (unlike the more widely known CRISPR-Cas9, which targets DNA). Typically, CRISPR is used to slice and edit genetic code, but in this case the researchers didn’t want ...

CRISPR Therapeutics is paying $25 million upfront to work on multiple siRNA targets with Sirius Tx with an early focus on the next-gen thrombotic disease asset SRSD107. That drug, Sirius’ lead ...

CRISPR Therapeutics stock is down more than 80% from the peak it reached in 2021. The first drug from CRISPR Therapeutics launched early last year, but annualized sales are still less than $60 ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Want to stay on top ...

In 2018, CRISPR Therapeutics advanced the first-ever CRISPR/Cas9 gene-edited therapy into the clinic to investigate the treatment of sickle cell disease and transfusion-dependent beta thalassemia.

Late last week, the world heard an incredible story: a baby with an exceptionally rare genetic condition seemed to have been treated with a single-use CRISPR treatment created just for him. Many won’t ...

Crispr Therapeutics said it is partnering with Sirius Therapeutics to develop and commercialize SRSD107, a small interfering RNA therapy to treat thromboembolic disorders. Under the agreement ...